Illuminating the Tumor Microenvironment Using Multiplex IF: Astronomy Accelerates Pathology

September 25, 2019 11:00 a.m. - 12:00 p.m. ET

On Wednesday, September 25, Dr. Alex Szalay and Dr. Janis Taube will present on, "Illuminating the Tumor Microenvironment Using Multiplex Immunofluorescence (IF): Astronomy Accelerates Pathology."

Johns Hopkins pathologist and cancer researcher, Janis Taube, has combined forces with astrophysicist/cosmologist, Alex Szalay; together, they are using the latest technology for mapping the galaxy and the stars to map the tumor microenvironment. By using this approach, they hope to gain a much better understanding of the structure and vulnerabilities of tumors and their response to immunotherapy.

The Data Science Seminar Series presents bi-weekly talks from innovators in the data science and cancer research communities both within and outside of NCI.

Alex Szalay, Ph.D.

Dr. Alexander Szalay, is a Bloomberg Distinguished Professor, the Alumni Centennial Professor of Astronomy, and Professor in the Department of Computer Science at Johns Hopkins University. He is the Director of the Institute for Data Intensive Science. He is a cosmologist, working on the statistical measures of the spatial distribution of galaxies and galaxy formation. He is a Corresponding Member of the Hungarian Academy of Sciences, and a Fellow of the American Academy of Arts and Sciences. Read more about Dr. Szalay.

Janis Taube, M.D., M.Sc.

Dr. Janis Taube is the director of Dermatopathology Division and Fellowship at Johns Hopkins University School of Medicine.  Her research interests center on immune evasion by solid tumors, specifically studying the PD-L1/PD-1 axis, and the identification of potential biomarkers of response to novel immunotherapies. This requires a focus on immunohistochemical and molecular methods for identifying cell surface antigens and signaling pathways in paraffin-embedded tissue. Dr. Taube’s laboratory described PD-L1-mediated adaptive immune resistance by melanoma, a finding that has now been extended to other tumor types. She also developed a robust immunohistochemistry assay and interpretation methods for studying PD-L1 as it relates to therapeutic response. Versions of this assay are now approved by the U.S. Food and Drug Administration for clinical use. Her ongoing research efforts focus on further characterizing the local tumor microenvironment using multiplex immunofluorescence with the aim of developing rational treatment combinations and improving patient selection algorithms. Read more about Dr. Taube.

Vote below about this page’s helpfulness.

Enter the characters shown in the image.